CAPTRUST Financial Advisors’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-28,742
Closed -$23.6K – 3530
2026
Q2
$23.6K Buy
28,742
+10,046
+54% +$9.49K ﹤0.01% 3192
2026
Q1
$17.2K Buy
18,696
+7,647
+69% +$9.26K ﹤0.01% 2970
2025
Q4
$14.1K Sell
11,049
-1,498
-12% -$2.01K ﹤0.01% 2725
2025
Q3
$16.3K Buy
12,547
+617
+5% +$808 ﹤0.01% 2611
2025
Q2
$14.3K Buy
+11,930
New +$13.2K ﹤0.01% 2484
2022
Q3
– Sell
-1,030
Closed -$2K – 3138
2022
Q2
$2K Hold
1,030
– – ﹤0.01% 4479
2022
Q1
$4K Hold
1,030
– – ﹤0.01% 4252
2021
Q4
$4K Sell
1,030
-41
-4% -$192 ﹤0.01% 4176
2021
Q3
$7K Sell
1,071
-3,110
-74% -$20.5K ﹤0.01% 3811
2021
Q2
$26K Sell
4,181
-44
-1% -$235 ﹤0.01% 2938
2021
Q1
$19K Buy
+4,225
New +$23.2K ﹤0.01% 3033

Other funds holding LAB

CAPTRUST Financial Advisors's LAB Position: Q3 2026 in Review

CAPTRUST Financial Advisors sold out of Standard BioTools (LAB) in Q3 2026, closing a stake of 28,742 shares — an estimated $23.6K sold.

CAPTRUST Financial Advisors first reported a position in LAB in Q1 2021 and held it in 11 quarters. The position peaked at $26K in Q2 2021. 104 funds tracked by Wall St. Rank hold LAB as of Q3 2026.

  • CAPTRUST Financial Advisors reported no remaining Standard BioTools position as of Q3 2026 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 28,742 Standard BioTools shares in Q3 2026, an estimated $23.6K.
  • CAPTRUST Financial Advisors first reported a position in Standard BioTools in Q1 2021 and held it in 11 quarters.
  • CAPTRUST Financial Advisors's Standard BioTools position peaked at $26K in Q2 2021.
  • 104 funds tracked by Wall St. Rank held Standard BioTools as of Q3 2026.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2026, filed 12 Nov 2026.